Research Scientist in Thoracic Cancer Genomics

Research Scientist in Thoracic Cancer Genomics

Vall d´Hebron Institute of Oncology (VHIO)

Barcelona, Spain

Vall d´Hebron Institute of Oncology (VHIO) currently seeks a Research Scientist in Throacic Cancer Genomics

Located within the Vall d´Hebron Barcelona Hospital Campus and connected to the Vall d´Hebron University Hospital (HUVH), VHIO is a leading reference in translational cancer science and clinical oncology, with a broad portfolio of clinical trials.

At any given time, between 25 – 30 clinical trials in thoracic malignancies are underway with novel agents in the pipeline that target a wide spectrum of cancer genes and pathways. This undertaking is facilitated through superb teamwork and close connectivity between our oncologists and cancer researchers of our Prescreening Program. More specifically, VHIO counts on its Cancer Genomics Group that serves as one of our state-of-the-art Core Technologies and is equipped with an n-Counter instrument (Nanostring), digital droplet PCR (BEAMing and Bio-Rad), qPCR; MiSeq and HiSeq 2500 (Illumina) sequencers and hardware.

We are seeking a highly motivated research scientist to join a recently created laboratory directed by Enriqueta Felip, Principal Investigator of VHIO’s Thoracic Tumors Group and Ana Vivancos, Principal Investigator of our Cancer Genomics Group.

The successful candidate will have solid communication skills with the capacity to work independently as well as part of a team. Prior experience in nucleic acid extraction of fresh/frozen and FFPE samples, library preparation for sequencing technologies, ddPCR, qPCR and RT-qPCR, etc. will be favorably considered. A solid background in cancer genomics is mandatory.

This is a full-time position and annual gross salary will be considered according to the profile, experience, and professional merits of the candidate.


PhD in Molecular Biology, Genetics, or any other related field.
Expertise in cancer genomics, cellular pathways commonly implicated in cancer, the clinical application of next generation sequencing and reporting results of genomic testing.
Detail-oriented with a capacity to critically analyze and interpret scientific data.
Excellent spoken and written English.
Strong organization skills and ability to deliver on deadlines.
Experience in interpreting clinical sequence variants and using tools such as cBioPortal, IGViewer, etc., will be favorably considered, as will knowledge of commonly used oncology/genomics databases such as dbSNP, COSMIC, ExAC, 1000 Genomes, etc.


Please send a CV and cover letter to, including “Ref. 19/2018” in the subject line of your email.

About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

VHIO’s translation toward precision oncology:

Please apply via recruiter’s website.

Quote Reference: 20/2018